News
-
GSK and Theravance have announced a Phase 3 study of fluticasone furoate (FF)/vilanterol (VI) (the Relvar Ellipta DPI) including Japanese COPD patients. In July 2013, GSK withdrew its application for Relvar for the treatment of… Read more . . .
-
Genoa Pharmaceuticals has announced that studies conducted in conjunction with McMaster University have shown that peak pirfenidone activity can be achieved by lung levels of the drug that remain for only a short period of… Read more . . .
-
Canada has approved GSK’s Incruse Ellipta umeclidinium (UMEC) DPI for the once-daily treatment of COPD, the first approval for its UMEC monotherapy, the company said. GSK received a positive opinion from the EMA’s Committee for… Read more . . .
-
US pharmaceutical company OPKO Health has announced that it will acquire Israeli device company Inspiro Medical whose only product is the Inspiromatic dry powder inhaler. In June 2013, Inspiro announced positive results from a study… Read more . . .
-
Alexza Pharmaceuticals has hired Winston R. Brown, Jr. as VP, Quality, the company has announced. Brown was most recently Global Head, Quality R&D – Pharmaceuticals, Biologics, and Vision Care Devices at Alcon Research. The company… Read more . . .
-
CDMO Molecular Profiles says that it has hired Charles D. Maher as head of US sales in order to “increase awareness and uptake of its pharmaceutical development services in the North American market.” The company’s… Read more . . .
-
Researchers from the University of St. Andrews, the University of Edinburgh, and St. Jude’s Children’s Research Hospital have published data demonstrating that a nasal spray designed to prevent the influenza virus from binding with receptors… Read more . . .
-
Gateway Analytical is inviting anyone attending RDD 2014 in Fajardo, Puerto Rico to a special VIP event on the evening of May 5. Attendees are invited to join Gateway for a sunset sail on a… Read more . . .
-
Inhaled drug developer Prosonix has announced a global licensing agreement with Mylan for its generic versions of GSK’s Flixotide and Flovent fluticasone propionate MDIs for the treatment of asthma. The deal covers two Prosonix MDIs,… Read more . . .
-
Theravance has initiated a dose-ranging Phase 2b study of its TD-4208 long-acting muscarinic antagonist (LAMA), the company announced. The study will compare four different dosages of TD-4208 and placebo, all delivered once daily via jet… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.